These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation. Turecek PL; Bossard MJ; Graninger M; Gritsch H; Höllriegl W; Kaliwoda M; Matthiessen P; Mitterer A; Muchitsch EM; Purtscher M; Rottensteiner H; Schiviz A; Schrenk G; Siekmann J; Varadi K; Riley T; Ehrlich HJ; Schwarz HP; Scheiflinger F Hamostaseologie; 2012; 32 Suppl 1():S29-38. PubMed ID: 22961422 [TBL] [Abstract][Full Text] [Related]
6. New high-technology products for the treatment of haemophilia. Pipe SW; Saint-Remy JM; Walsh CE Haemophilia; 2004 Oct; 10 Suppl 4():55-63. PubMed ID: 15479373 [TBL] [Abstract][Full Text] [Related]
7. Recent advances in the understanding of the molecular biology of hemophilia A: possible implications towards a more effective therapeutic regime. Scheiflinger F; Dorner F Wien Klin Wochenschr; 1999 Mar; 111(5):172-80. PubMed ID: 10226347 [TBL] [Abstract][Full Text] [Related]
8. Factor VIII half-life and intensity of treatment in hemophilic patients. Vicente V Haematologica; 2005 Apr; 90(4):437. PubMed ID: 15820932 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic properties of recombinant factor VIII compared with a monoclonally purified concentrate (Hemofil M). The Recombinate Study Group. Morfini M; Longo G; Messori A; Lee M; White G; Mannucci P Thromb Haemost; 1992 Oct; 68(4):433-5. PubMed ID: 1448776 [TBL] [Abstract][Full Text] [Related]
10. New products for the treatment of haemophilia. Laffan M Br J Haematol; 2016 Jan; 172(1):23-31. PubMed ID: 26456702 [TBL] [Abstract][Full Text] [Related]
11. Factor VIII half-life and clinical phenotype of severe hemophilia A. van Dijk K; van der Bom JG; Lenting PJ; de Groot PG; Mauser-Bunschoten EP; Roosendaal G; Grobbee DE; van den Berg HM Haematologica; 2005 Apr; 90(4):494-8. PubMed ID: 15820945 [TBL] [Abstract][Full Text] [Related]
12. Liposomal approach towards the development of a longer-acting factor VIII. Powell JS Haemophilia; 2007 Sep; 13 Suppl 2():23-8. PubMed ID: 17685920 [TBL] [Abstract][Full Text] [Related]
13. Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy. Baru M; Carmel-Goren L; Barenholz Y; Dayan I; Ostropolets S; Slepoy I; Gvirtzer N; Fukson V; Spira J Thromb Haemost; 2005 Jun; 93(6):1061-8. PubMed ID: 15968389 [TBL] [Abstract][Full Text] [Related]
14. The improved factor concentrate. Lillicrap D Hamostaseologie; 2009 Jan; 29(1):71-3. PubMed ID: 19151851 [TBL] [Abstract][Full Text] [Related]
15. Enhancement of the efficacy of therapeutic proteins by formulation with PEGylated liposomes; a case of FVIII, FVIIa and G-CSF. Yatuv R; Robinson M; Dayan I; Baru M Expert Opin Drug Deliv; 2010 Feb; 7(2):187-201. PubMed ID: 20095942 [TBL] [Abstract][Full Text] [Related]
17. Extending half-life in coagulation factors: where do we stand? Lillicrap D Thromb Res; 2008; 122 Suppl 4():S2-8. PubMed ID: 18929522 [TBL] [Abstract][Full Text] [Related]
18. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A. Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610 [TBL] [Abstract][Full Text] [Related]
19. [Long-term prophylaxis in congenital haemophilia with inhibitors - experiences with rFVIIa]. Auerswald G Hamostaseologie; 2007 May; 27(2):123-8. PubMed ID: 17479176 [TBL] [Abstract][Full Text] [Related]
20. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic. Bell SJ; Fam CM; Chlipala EA; Carlson SJ; Lee JI; Rosendahl MS; Doherty DH; Cox GN Bioconjug Chem; 2008 Jan; 19(1):299-305. PubMed ID: 18020402 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]